With recent advances in precision medicine, clinicogenomic data has become increasingly important. In this panel discussion featuring SMEs from leading pharmaceutical, molecular testing, and healthcare companies, we will explore the following themes and topics:
The importance of diverse phenotypic & genotypic profiles
Improving regulatory approval outcomes
Identifying new biomarkers for treatment response
Label expansion by expanding existing treatments to new cohorts or conditions
Using RWE as digital control arms for clinical trials
Who should attend?
- Translational Research
- Epidemiology
- Biomarker Leaders
- Medical Affair
- HEOR
- Clinical Development
- RWD&A Strategy and Partnership leaders
Click here to find additional details and registration information.
Related Content
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
In this webinar, Dr. Joseph Zabinski will discuss the digital phenotyping process and several concrete applications to demonstrate how AI can add value to analyses of the patient journey across the life sciences spectrum.
Beyond Accelerated Approvals: External Control Arms
Hear this panel's discussion on the strategic use of external control arms and, if done correctly, how they can help bring products to market in a shorter time and for lower costs.